OM336 in Autoimmune Cytopenias

Recruiting now · Phase 1

Conditions studied: AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia, ITP - Immune Thrombocytopenia

In brief

An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.

Key facts

Study ID

NCT07083960

Run by

Lakefront Biotherapeutics West LLC

People needed

32

Starts

2025-08-01

Expected to finish

2027-09-01

Last updated by the study team

2026-07-14

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• The Canberra Hospital — Canberra, Australian Capital Territory, Australia (enrolling)
• Liverpool Hospital — Sydney, New South Wales, Australia (enrolling)
• Icon Cancer Center South Brisbane — Brisbane, Queensland, Australia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.